The Global Prostate Cancer Market is expected to grow at a high CAGR during the forecasting period (2020-2027).
Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men. The average age of a prostate cancer diagnosis is 66 years.
However, one-time screening and early diagnosis are likely to increase the success rate of treatment.
The global Prostate Cancer market is anticipated to reach a value of USD 18 billion by 2026.
Increasing disease prevalence will act as the primary driver for market growth.
Around 200,000 men are diagnosed with it every year, and most of them are over the age of 50. It is estimated that nearly 30,000 men died because of prostate cancer in 2018.
Other market drivers include rapid advancement in oncology screening and diagnostics as well as innovations in drug development.
However, the high cost associated with diagnostic tests and adverse effects of treatment will affect market growth.
An increasing trend is to bring effective immune-based cancer treatments to patients with prostate cancer.
Immunotherapy is a promising new treatment currently being developed in research. Provence, also known as sipuleucel-T is the only FDA-approved immunotherapy for prostate cancer.
The Global Prostate Cancer market report segments the market by therapy, by end-user, and by region.
Based on therapy, the market is segmented into hormonal treatment; chemotherapy; immunotherapy; radiation and focal therapies.
Based on the end user, the global Prostate Cancer market has been segmented into hospitals, ambulatory surgical centers, and specialty clinics.Hospital end-user type segment is expected to account for the highest share.
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW. North America is the leading global market with the largest revenue share in 2017 owing to the high prevalence of the disease in the US. Next to skin cancer, prostate cancer is the most common cancer in American men. As per the American Cancer Society’s, about 164,690 new cases of prostate cancer will be diagnosed in 2018. Hence, this region witnesses high investment in R&D for the development of newer immunotherapies.
By Therapy Type
Ambulatory Surgical Centers
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World.
Visualize the composition of Prostate Cancer market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for crucial Prostate Cancer products of all major market players.
Equipment Suppliers/ Buyers
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
1.1 Research Methodology
1.2 Scope of the Report
2.1 Key Trends & Developments
3.1 Market Drivers
3.1.1 Innovations in drug development
3.2 Market Restraints
3.2.1 The high cost associated with diagnostic tests
3.2.2 Adverse effects of treatment
3.2.3 Castration-resistant prostate cancer
3.2.4 Prostate cancer patients
3.3 Threats and Opportunities
3.2 Porter’s 5 Forces
4.1 By Therapy Type
4.1.1 Hormone therapy
22.214.171.124 External-beam radiation therapy
4.1.5 Focal therapies
4.1.7 High-intensity focused ultrasound (HIFU)
4.2 By End-User
4.2.2 Ambulatory Surgical Centers
4.2.3 Specialty Clinics
5.1. North America
5.1.1. The USA
5.2.3. The UK
5.2.6. Rest of Europe
5.3. Asia Pacific
5.3.5. Rest of Asia Pacific
5.4. South America
5.4.3. Rest of South America
5.5 Rest of the World
6.1. Market Share Analysis
6.2. Mergers and Acquisitions Analysis
6.3. New Product Launches
7.1 Johnson & Johnson
7.2 Astella, Inc.
7.3 Sanofi Aventis
7.5 Bayer AG
7.7 Valent Pharmaceuticals LLC
8.2 List of Tables
8.3 Expert Panel Validation
8.5 Contact Us
Q. At what CAGR is the Prostate Cancer Market anticipated to augment?
A. The Prostate Cancer Market is projected to strike high CAGR
Q. Which region holds major market share?
A. North America is the leading global market with the largest revenue share in 2017 owing to the high prevalence of the disease in the US.
Q. What is the key driving factors of the Prostate Cancer Market?
A. Increasing disease prevalence will act as the primary driver for market growth.
Get your FREE SAMPLE PROPOSAL with a single click!